LinkedIn Image

Expert Practice℠ in Gynecologic Malignancies

Meeting Overview

Join us for this interactive, case-based program to enhance your knowledge of the latest therapeutic strategies for gynecologic malignancies, including newly-diagnosed and recurrent ovarian cancer, cervical cancer, and uterine leiomyosarcoma. During this full day meeting, you will have the opportunity to interact with experts in the field, gain insight into their management of patients, and discuss challenges that you face in your practice.

Agenda

Friday, 20 October 2017

19.30 “Meet the Experts” dinner

Saturday, 21 October 2017

08.30 Welcome, introduction, and demographics
Nicoletta Colombo, MD, and Ignace Vergote, MD, PhD
08.50 Keynote lecture—Immunotherapy: An evolving strategy in gynecologic cancers
Eric Pujade-Lauraine, MD, PhD
09.15 Audience questions and faculty comments
09.20 Case #1—Newly diagnosed advanced ovarian cancer: Selecting front-line therapy
Jalid Sehouli, MD, PhD
09.50 Audience questions and faculty comments
10.05 Case #2—Recurrent ovarian cancer (platinum therapy–free interval [TFIp] 6-12 months): Evaluating treatment options
Nicoletta Colombo, MD
10.35 Audience questions and faculty comments
10.50 Coffee break
11.10 Case #3—Treatment of recurrent ovarian cancer (TFIp>12 months) and the role of maintenance therapy
Antonio González-MartÍn, MD
11.40 Audience questions and faculty comments
11.55 Case #4—Platinum-resistant ovarian cancer: Is there a light at the end of the tunnel?
Ignace Vergote, MD, PhD
12.25 Audience questions and faculty comments
12.40 Lunch
13.40 Clinical opinion poll questions: Challenging the experts
14.10 Case #5—Uterine leiomyosarcoma: Diagnostic and therapeutic considerations
Philipp Harter, MD, PhD
14.40 Audience questions and faculty comments
14.55 Case #6—Optimizing management of advanced cervical cancer
Nicoletta Colombo, MD
15.25 Audience questions and faculty comments
15.40 Concluding remarks
Nicoletta Colombo, MD, and Ignace Vergote, MD, PhD

Faculty

Co-Chairs
  • Nicoletta Colombo, MDUniversity of Milan–Bicocca
    European Institute of Oncology
    Milan, Italy
  • Ignace Vergote, MD, PhDUniversity Hospitals Leuven
    Leuven, European Union
Faculty
  • Antonio González-Martín, MDClínica Universidad de Navarra
    Madrid, Spain
  • Philipp Harter, MD, PhDKliniken Essen-Mitte
    Essen, Germany
  • Eric Pujade-Lauraine, MD, PhDCentre Hospitalier Universitaire Hôtel-Dieu
    Paris, France
  • Jalid Sehouli, MD, PhDUniversity Hospital Charité–Campus Virchow Klinikum
    Berlin, Germany

Target Audience

This educational activity is designed for European gynecologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and management of gynecologic malignancies.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Describe the rationale and ongoing trials evaluating immunotherapies for the treatment of gynecologic cancers
  • Select optimal management for newly diagnosed advanced ovarian cancer, including the use of neoadjuvant chemotherapy and targeted therapy in the front-line therapy setting
  • Explain the role of predictive biomarkers such as BRCA mutations and homologous recombination deficiency (HRD) score for treatment with PARP inhibitors
  • Identify patients with relapsed ovarian cancer who may benefit from secondary debulking surgery, targeted maintenance therapy, or use of platinum-free chemotherapy
  • Describe management of treatment-related adverse events, including optimal prophylaxis of chemotherapy-induced nausea and vomiting (CINV)
  • Evaluate treatment options for patients with uterine sarcoma and other uterine cancers
  • Assess standard and emerging therapies for advanced cervical cancer

Continuing Education

Expert Practice℠ in Gynecologic Malignancies held in Berlin, Germany on 21/10/2017 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 5 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Ärztekammer Berlin

prIME Oncology has received 7 CME-credits category A from the Ärztekammer Berlin for the German participants for “Expert Practice℠ in Gynecologic Malignancies” meeting (VNR 2761102017042290003).

Disclosures

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Support

This educational activity is supported by grants from ImmunoGen, Inc.; PharmaMar S.A.; and Tesaro.

Register Now

To apply for a travel grant, click on the Register Now button.

Date and Location

Saturday, 21 October 2017
08.30 – 15.40

Hotel Berlin, Berlin
Lützowplatz 17
Berlin, Germany

Provider

This activity is provided by prIME Oncology.

SUNSHINE ACT/EFPIA DISCLOSURE STATEMENT

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.